Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-22

Study Completion Date

2022-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endobronchial bleeding is a relatively common complication of diagnostic bronchoscopy. Both tranexamic acid and adrenaline are used topically for the control of endobronchial bleeding. The aim of this study is to compare the efficacy of tranexamic acid with adrenaline in controlling iatrogenic endobronchial bleeding after diagnostic bronchoscopy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prophylactic Tranexamic Acid Versus Adrenaline During Flexible Bronchoscopy

NCT06145191

Bleeding Hemoptysis

COMPLETED NA

Control of Iatrogenic Endobronchial Bleeding by Tranexamic Acid, Adrenalin and Hemagglutinase

NCT06149091

Iatrogenic Endobronchial Bleeding

RECRUITING EARLY_PHASE1

Topical Instillation of Tranexamic Aacid in Bronchoscopy to Decrease Bleeding During Entobronchial & Transbronchial Biopsiy: a Prospective Double Blind Placebo Controlled Study

NCT02219152

Bronchoscopy Biopsy

UNKNOWN PHASE2

Prophylactic Endobronchial Tranexamic Acid to Reduce Bleeding in Transbronchial Cryobiopsy

NCT06266546

Hemorrhage Lung Endobronchial Mass

ACTIVE_NOT_RECRUITING PHASE3

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

NCT07131592

Drain Output After Breast Reduction Surgery Breast Reductions

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bleeding Hemoptysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tranexamic acid

Group Type EXPERIMENTAL

Tranexamic acid

Intervention Type DRUG

Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.

Adrenaline

Group Type EXPERIMENTAL

Adrenaline

Intervention Type DRUG

Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic acid

Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.

Intervention Type DRUG

Adrenaline

Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with endobronchial bleeding during diagnostic bronchoscopy that was not successfully controlled with cold (4°C) normal saline (3 aliquots of 5ml during 60sec)

Exclusion Criteria

* Any patient with a contraindication for diagnostic flexible bronchoscopy
* Coagulopathy (PV INR \>1.3)
* Thrombocytopenia (\<50x10\^9) or anemia (hgb \<80 g/L)
* Direct oral anticoagulant, low molecular weight heparin or antiplatelet drug therapy
* Thrombophilia, history of pulmonary embolism or deep vein thrombosis
* Contraindication for endobronchial application of adrenaline
* Coronary heart disease, cerebrovascular disease, history of tachyarrhythmia
* Uncontrolled pulmonary hypertension
* Cardiovascular decompensation
* Severe hypoxia (PaO2 \<60mmHg, SaO2 \<90% with an FiO2 \>=60%)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No